Page 90 - Read Online

Huang et al. J Cancer Metastasis Treat 2019;5:34 I http://dx.doi.org/10.20517/2394-4722.2018.94 Page 17 of 18

cancer patients. Proc Natl Acad Sci U S A 2013;110:21083-8.
77. Trapp E, Janni W, Schindlbeck C, Juckstock J, Andergassen U, et al. Presence of Circulating Tumor Cells in High-Risk Early Breast
Cancer During Follow-Up and Prognosis. J Natl Cancer Inst 2019;111:380-7.
78. Yang C, Shi D, Wang S, Wei C, Zhang C, et al. Prognostic value of pre- and post-operative circulating tumor cells detection in colorectal
cancer patients treated with curative resection: a prospective cohort study based on ISET device. Cancer Manag Res 2018;10:4135-44.
79. Nicola N, Antonio R, Alessandro M, Simona S, Simona B, et al. Prognostic value of circulating tumor cells’ reduction in patients with
extensive small-cell lung cancer. Lung Cancer 2014;85:314-9.
80. Smerage JB, Barlow WE, Hortobagyi GN, Winer EP, Leyland-Jones B, et al. Circulating tumor cells and response to chemotherapy in
metastatic breast cancer: SWOG S0500. J Clin Oncol 2014;32:3483-9.
81. Wen YF, Cheng TT, Chen XL, Huang WJ, Peng HH, et al. Elevated circulating tumor cells and squamous cell carcinoma antigen levels
predict poor survival for patients with locally advanced cervical cancer treated with radiotherapy. PLoS One 2018;13:e0204334.
82. Wu ZX, Liu Z, Jiang HL, Pan HM, Han WD. Circulating tumor cells predict survival benefit from chemotherapy in patients with lung
cancer. Oncotarget 2016;7:67586-96.
83. Bidard FC, Michiels S, Riethdorf S, Mueller V, Esserman LJ, et al. Circulating Tumor Cells in Breast Cancer Patients Treated by
Neoadjuvant Chemotherapy: A Meta-analysis. J Natl Cancer Inst 2018;110:560-7.
84. Swaika A, Hammond WA, Joseph RW. Current state of anti-PD-L1 and anti-PD-1 agents in cancer therapy. Mol Immunol 2015;67:4-17.
85. Hong X, Sullivan RJ, Kalinich M, Kwan TT, Giobbie-Hurder A, et al. Molecular signatures of circulating melanoma cells for monitoring
early response to immune checkpoint therapy. Proc Natl Acad Sci U S A 2018;115:2467-72.
86. Namatame N, Tamaki N, Yoshizawa Y, Okamura M, Nishimura Y, et al. Antitumor profile of the PI3K inhibitor ZSTK474 in human
sarcoma cell lines. Oncotarget 2018;9:35141-61.
87. Grunwald V, Keilholz U, Boehm A, Guntinas-Lichius O, Hennemann B, et al. TEMHEAD: a single-arm multicentre phase II study of
temsirolimus in platin- and cetuximab refractory recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN) of
the German SCCHN Group (AIO). Ann Oncol 2015;26:561-7.
88. Mazel M, Jacot W, Pantel K, Bartkowiak K, Topart D,et al. Frequent expression of PD-L1 on circulating breast cancer cells. Mol Oncol
2015;9:1773-82.
89. Kim YR, Yoo JK, Jeong CW, Choi JW. Selective killing of circulating tumor cells prevents metastasis and extends survival. J Hematol
Oncol 2018;11:114.
90. Mouliere F, Chandrananda D, Piskorz AM, Moore EK, Morris J, et al. Enhanced detection of circulating tumor DNA by fragment size
analysis. Sci Transl Med 2018;10.
91. Nakamura K, Sawada K, Yoshimura A, Kinose Y, Nakatsuka E, et al. Clinical relevance of circulating cell-free microRNAs in ovarian
cancer. Mol Cancer 2016;15:48.
92. Melo SA, Luecke LB, Kahlert C, Fernandez AF, Gammon ST,et al. Glypican-1 identifies cancer exosomes and detects early pancreatic
cancer. Nature 2015;523:177-82.
93. Halvorsen AR, Sandhu V, Sprauten M, Flote VG, Kure EH, et al. Circulating microRNAs associated with prolonged overall survival in
lung cancer patients treated with nivolumab. Acta Oncol 2018;57:1225-31.
94. Leon SA, Shapiro B, Sklaroff DM, Yaros MJ. Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res
1977;37:646-50.
95. Ilie M, Szafer-Glusman E, Hofman V, Chamorey E, Lalvee S, et al. Detection of PD-L1 in circulating tumor cells and white blood cells
from patients with advanced non-small-cell lung cancer. Ann Oncol 2018;29:193-9.
96. Strati A, Koutsodontis G, Papaxoinis G, Angelidis I, Zavridou M, et al. Prognostic significance of PD-L1 expression on circulating tumor
cells in patients with head and neck squamous cell carcinoma. Ann Oncol 2017;28:1923-33.
97. Boffa DJ, Graf RP, Salazar MC, Hoag J, Lu D,et al. Cellular Expression of PD-L1 in the Peripheral Blood of Lung Cancer Patients is
Associated with Worse Survival. Cancer Epidemiol Biomarkers Prev 2017;26:1139-45.
98. Kulasinghe A, Perry C, Kenny L, Warkiani ME, Nelson C, et al. PD-L1 expressing circulating tumour cells in head and neck cancers.
BMC Cancer 2017;17:333.
99. Hall CS, Karhade M, Laubacher BA, Kuerer HM, Krishnamurthy S, et al. Circulating Tumor Cells and Recurrence After Primary
Systemic Therapy in Stage III Inflammatory Breast Cancer. J Natl Cancer Inst 2015;107.
100. Bidard F-C, Peeters DJ, Fehm T, Nolé F, Gisbert-Criado R, et al. Clinical validity of circulating tumour cells in patients with metastatic
breast cancer: a pooled analysis of individual patient data. The Lancet Oncology 2014;15:406-14.
101. Barbazan J, Muinelo-Romay L, Vieito M, Candamio S, Diaz-Lopez A, et al. A multimarker panel for circulating tumor cells detection
predicts patient outcome and therapy response in metastatic colorectal cancer. Int J Cancer 2014;135:2633-43.
102. Romiti A, Raffa S, Di Rocco R, Roberto M, Milano A, et al. Circulating tumor cells count predicts survival in colorectal cancer patients. J
Gastrointestin Liver Dis 2014;23:279-84.
103. Zhou J, Dong F, Cui F, Xu R, Tang X. The role of circulating tumor cells in evaluation of prognosis and treatment response in advanced
non-small-cell lung cancer. Cancer Chemother Pharmacol 2017;79:825-33.
104. Muinelo-Romay L, Vieito M, Abalo A, Nocelo MA, Baron F, et al. Evaluation of Circulating Tumor Cells and Related Events as
Prognostic Factors and Surrogate Biomarkers in Advanced NSCLC Patients Receiving First-Line Systemic Treatment. Cancers (Basel)
2014;6:153-65.
105. Messaritakis I, Politaki E, Kotsakis A, Dermitzaki EK, Koinis F, et al. Phenotypic characterization of circulating tumor cells in the
peripheral blood of patients with small cell lung cancer. PLoS One 2017;12:e0181211.